Clinical Trials Browser

Hematologic Neoplasms × rasburicase × Clear all

NCT04745910 2025-12-18

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Phase 4 Active not recruiting

Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

NCT01200485 2020-01-31

Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Phase 2 Completed

55 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Tumor Lysis Syndrome, Leukemia, Myeloid, Acute, Hematologic Neoplasms